![]() MacQuitty continued, “The vision that Roland brought to Lightspeed in 2016 of a novel bispecific platform that could provide life changing therapies was compelling. Jonathan MacQuitty, Sector Head for Life Sciences at Lightspeed, who joined Teneobio‘s Board at the time of the Series A Preferred round, commented, “With the Amgen acquisition and the recent exercise by Abbvie of its option to acquire TeneoOne, Roland and the team at newly formed Ancora Biotech LLC can now focus on these remaining spin-offs.”ĭr. In 2016 Lightspeed Venture Partners led Teneobio’s Series A Preferred round, Teneobio’s only institutional financing, along with Sutter Hill Ventures. We strongly believe in the potential of TNB-486 which targets malignant B-cells, TNB-738 targeting inflammation and our anti-HBVxCD3 that will target liver cells chronically infected with Hepatitis B virus.” In parallel, Teneobio’s former shareholders and their representatives will oversee development of the former Teneobio affiliates that were not part of the Amgen transaction. Roland Buelow, former CEO of Teneobio, Inc., and CEO of Ancora Biotech said, “We are excited that Amgen will advance Teneobio’s pipeline of assets in the clinic and further apply Teneobio’s technologies. TeneoTen’s anti-HBVxCD3 involves a new approach to potentially cure chronic hepatitis B. TeneoTwo’s TNB-486 is currently in phase I clinical studies for the treatment of B-cell malignancies, while TeneoFour’s TNB-738, targeting inflammatory diseases, will enter Phase I in early 2022. These spin-offs were not part of the acquisition by Amgen of Teneobio. (anti-CD38 enzyme inhibitor TNB-738) and TeneoTen, Inc. ![]() Ancora Biotech announced, in connection with the closing of the acquisition of Teneobio, Inc., by Amgen Inc., that Teneobio’s former shareholders and their representatives will provide oversight of three previous affiliates of Teneobio, including TeneoTwo, Inc.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |